Literature DB >> 23334901

Echocardiographic parameters to predict inadequate defibrillation safety margin in patients receiving implantable cardioverter defibrillators for primary prevention.

Sachin Kumar Amruthlal Jain1, Hamid Ghanbari, Rayan Hourani, Timothy R Larsen, Marcos Daccarett, Christian Machado.   

Abstract

BACKGROUND: Implantable cardioverter defibrillators (ICDs) have become an important part of the management of patients with congestive heart failure. At the time of ICD implantation, ventricular fibrillation (VF) is induced to assess adequate energy required for defibrillation. There are multiple parameters which influence the defibrillation safety margin (DSM); however, these factors are not well-established when ICDs are implanted for the primary prevention of sudden cardiac death (SCD) in patients with severe systolic dysfunction. We evaluated multiple clinical and echocardiographic parameters as predictors of adequate DSM in patients referred for ICD implantation for the primary prevention of SCD.
METHODS: We prospectively enrolled 41 patients for ICD implantation with clinical indications for the primary prevention of SCD. Two blinded independent readers evaluated the prespecified echocardiographic parameters. These included left ventricular (LV) mass, indices of right ventricular and LV systolic and diastolic functions, and LV geometric dimensions. Basic clinical demographics, including age, gender, comorbidities, and etiology of cardiomyopathy, were also evaluated. DSM was established using our standard protocol for defibrillation testing which includes VF with successful first shock terminating VF at a value at least 10 J below the maximum output of the implanted device. High defibrillation thresholds (DFT) were defined as >21 J.
RESULTS: The mean age is 61.8 ± 14.7 years, with men comprising the majority of the patients (73 %). The only clinical variables which predicted the high DFT were age (in years) (54.5 ± 17.5 vs. 65.7 ± 11.3, p = 0.044), QRS duration (in milliseconds) (116.0 ± 29.5 vs. 110.5 ± 21.8, p = 0.03), LV mass (in grams) (241.0 ± 77.9 vs. 181.9 ± 52.3, p = 0.006), and LV mass index (in grams per square meter) (111.1 ± 38.2 vs. 86.4 ± 21.1, p = 0.02). On multivariate logistic regression analysis, LV mass was the only independent predictor of low DFT (≤22 J) in patients with ICD implanted for the primary prevention of SCD.
CONCLUSION: LV mass may help predict an adequate DSM in patients who are referred for ICD implantation for the primary prevention of SCD. These results may help distinguish the patients who may require high-energy devices prior to the implantation procedure. These results may help distinguish patients requiring high-energy devices, coils, or advanced programming prior to implantation and appropriate referral to electrophysiologists.

Entities:  

Mesh:

Year:  2013        PMID: 23334901     DOI: 10.1007/s10840-012-9764-4

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  22 in total

1.  A protocol for patients with cardiovascular implantable devices undergoing magnetic resonance imaging (MRI): should defibrillation threshold testing be performed post-(MRI).

Authors:  Peter Thomas Burke; Hamid Ghanbari; Patrick B Alexander; Michael K Shaw; Marcos Daccarett; Christian Machado
Journal:  J Interv Card Electrophysiol       Date:  2010-01-29       Impact factor: 1.900

Review 2.  Clinical competency statement: Training pathways for implantation of cardioverter defibrillators and cardiac resynchronization devices.

Authors:  Anne B Curtis; Kenneth A Ellenbogen; Stephen C Hammill; David L Hayes; Dwight W Reynolds; David J Wilber; Michael E Cain
Journal:  Heart Rhythm       Date:  2004-09       Impact factor: 6.343

3.  Defibrillation threshold testing: is one shock enough?

Authors:  Edward P Gerstenfeld
Journal:  Heart Rhythm       Date:  2005-02       Impact factor: 6.343

4.  Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).

Authors:  Daniel B Mark; Charlotte L Nelson; Kevin J Anstrom; Sana M Al-Khatib; Anastasios A Tsiatis; Patricia A Cowper; Nancy E Clapp-Channing; Linda Davidson-Ray; Jeanne E Poole; George Johnson; Jill Anderson; Kerry L Lee; Gust H Bardy
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

5.  Defibrillation threshold testing: is it really necessary at the time of implantable cardioverter-defibrillator insertion?

Authors:  Andrea M Russo; William Sauer; Edward P Gerstenfeld; Henry H Hsia; David Lin; Joshua M Cooper; Sanjay Dixit; Ralph J Verdino; Hemal M Nayak; David J Callans; Vickas Patel; Francis E Marchlinski
Journal:  Heart Rhythm       Date:  2005-05       Impact factor: 6.343

6.  Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system.

Authors:  Denice M Hodgson; Mary R Olsovsky; Stephen R Shorofsky; Barry Daly; Michael R Gold
Journal:  Pacing Clin Electrophysiol       Date:  2002-04       Impact factor: 1.976

7.  Relation of the intraoperative defibrillation threshold to successful postoperative defibrillation with an automatic implantable cardioverter defibrillator.

Authors:  F E Marchlinski; B Flores; J M Miller; C D Gottlieb; W C Hargrove
Journal:  Am J Cardiol       Date:  1988-09-01       Impact factor: 2.778

8.  Defibrillation threshold testing: tradition or necessity?

Authors:  Christof Kolb; Stylianos Tzeis; Bernhard Zrenner
Journal:  Pacing Clin Electrophysiol       Date:  2009-05       Impact factor: 1.976

Review 9.  Management of high defibrillation threshold.

Authors:  Eric R Uyguanco; Aaron Berger; Adam S Budzikowski; Moshe Gunsburg; John Kassotis
Journal:  Expert Rev Cardiovasc Ther       Date:  2008-10

10.  Complications associated with defibrillation threshold testing: the Canadian experience.

Authors:  David Birnie; Stanley Tung; Christopher Simpson; Eugene Crystal; Derek Exner; Felix-Alejandro Ayala Paredes; Andrew Krahn; Ratika Parkash; Yaariv Khaykin; Francois Philippon; Peter Guerra; Shane Kimber; Douglas Cameron; Jeffrey S Healey
Journal:  Heart Rhythm       Date:  2007-11-28       Impact factor: 6.343

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.